ATE358171T1 - Hydrophobe aminosäuren enthaltende trockene zusammensetzung - Google Patents

Hydrophobe aminosäuren enthaltende trockene zusammensetzung

Info

Publication number
ATE358171T1
ATE358171T1 AT00987720T AT00987720T ATE358171T1 AT E358171 T1 ATE358171 T1 AT E358171T1 AT 00987720 T AT00987720 T AT 00987720T AT 00987720 T AT00987720 T AT 00987720T AT E358171 T1 ATE358171 T1 AT E358171T1
Authority
AT
Austria
Prior art keywords
composition containing
dry composition
amino acid
hydrophobic amino
saccharide
Prior art date
Application number
AT00987720T
Other languages
English (en)
Inventor
Chikamasa Yamashita
Masaaki Odomi
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Application granted granted Critical
Publication of ATE358171T1 publication Critical patent/ATE358171T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/16—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Anti-Oxidant Or Stabilizer Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
AT00987720T 1999-12-24 2000-12-22 Hydrophobe aminosäuren enthaltende trockene zusammensetzung ATE358171T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP36805399 1999-12-24

Publications (1)

Publication Number Publication Date
ATE358171T1 true ATE358171T1 (de) 2007-04-15

Family

ID=18490866

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00987720T ATE358171T1 (de) 1999-12-24 2000-12-22 Hydrophobe aminosäuren enthaltende trockene zusammensetzung

Country Status (12)

Country Link
US (1) US20030045481A1 (de)
EP (1) EP1254944B1 (de)
KR (1) KR100709792B1 (de)
CN (1) CN1253528C (de)
AT (1) ATE358171T1 (de)
AU (1) AU784885B2 (de)
CA (1) CA2395438C (de)
DE (1) DE60034149T2 (de)
DK (1) DK1254944T3 (de)
ES (1) ES2281370T3 (de)
PT (1) PT1254944E (de)
WO (1) WO2001048117A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10149030A1 (de) * 2001-10-05 2003-04-10 Viscum Ag Stabile galenische gefriergetrocknete Arzneimittelzubereitung von rViscumin
JP5057648B2 (ja) * 2002-09-26 2012-10-24 塩野義製薬株式会社 安定化されたタンパク組成物
US7023217B1 (en) 2004-12-16 2006-04-04 Honeywell International Inc. Method and apparatus for determining wear of resistive and conductive elements
JP5034944B2 (ja) * 2005-07-27 2012-09-26 味の素株式会社 インターフェロン作用物質の活性増強剤
ES2387661B1 (es) * 2010-12-10 2013-10-31 Biolan Microbiosensores S.L. Proceso de purificación y estabilización de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3); y uso de la enzima gluconato deshidrogenasa (gadh, ec 1.1.99.3).

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4623717A (en) * 1980-03-05 1986-11-18 Miles Laboratories, Inc. Pasteurized therapeutically active protein compositions
JPS58164683A (ja) * 1982-03-25 1983-09-29 Takeda Chem Ind Ltd 安定化された固体組成物
GB8703718D0 (en) * 1987-02-18 1987-03-25 Dalgety Uk Ltd Colour production
US6582728B1 (en) * 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
DE4242863A1 (de) * 1992-12-18 1994-06-23 Boehringer Mannheim Gmbh Stabile lyophilisierte pharmazeutische Zubereitungen von G-CSF
US5368879A (en) * 1993-07-23 1994-11-29 R. J. Reynolds Tobacco Company Flavorful dry food condiment and process of providing the same
AU696387B2 (en) * 1994-05-18 1998-09-10 Inhale Therapeutic Systems, Inc. Methods and compositions for the dry powder formulation of interferons
TW403653B (en) * 1995-12-25 2000-09-01 Otsuka Pharma Co Ltd Dry compositions
WO2000000221A1 (en) * 1998-06-26 2000-01-06 Otsuka Pharmaceutical Co., Ltd. Water soluble dry compositions
JP2000247903A (ja) * 1999-03-01 2000-09-12 Chugai Pharmaceut Co Ltd 長期安定化製剤

Also Published As

Publication number Publication date
DE60034149T2 (de) 2007-12-13
DK1254944T3 (da) 2007-07-02
CN1253528C (zh) 2006-04-26
AU784885B2 (en) 2006-07-20
KR20020070327A (ko) 2002-09-05
WO2001048117A1 (fr) 2001-07-05
EP1254944B1 (de) 2007-03-28
AU2401501A (en) 2001-07-09
CN1413241A (zh) 2003-04-23
US20030045481A1 (en) 2003-03-06
CA2395438A1 (en) 2001-07-05
EP1254944A1 (de) 2002-11-06
EP1254944A4 (de) 2004-09-08
CA2395438C (en) 2009-10-13
DE60034149D1 (de) 2007-05-10
KR100709792B1 (ko) 2007-04-19
PT1254944E (pt) 2007-06-08
ES2281370T3 (es) 2007-10-01
HK1052946A1 (en) 2003-10-03

Similar Documents

Publication Publication Date Title
NO941937D0 (no) Sakarinderivater som inhiberer proteolytiske enzymer
ES2179910T3 (es) Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
BR0012046A (pt) Composto heterocìclico, composição farmacêutica, inibidor de ativação de ap-1 ou um inibidor da ativação de nf-kappab, inibidor da produção de citocina inflamatória, e, inibidor da produção de metaloprotease de matriz ou inibidor da expressão do fator de adesão de célula inflamatória
DK1087960T3 (da) Makrocykliske analoger og fremgangsmåder til deres anvendelse og fremstilling
CY1110906T1 (el) Φαρμακευτικη συνθεση για ρινικη χορηγηση φεντανυλης
DK555089D0 (da) Farmaceutiske praeparater indeholdende n-(3,4-dimethoxycinnamoyl)anthranilsyre
PT1311285E (pt) Composicao farmaceutica liquida contendo um derivado de eritropoietina
MXPA03001495A (es) Derivados de fenilalanina novedosos.
BR9813284B1 (pt) aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
ATE195721T1 (de) Lipopolyamine als transfectionsmittel und ihre pharmazeutischen anwendungen
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
PT929547E (pt) Derivados da benzamidina substituidos por derivados de aminoacidos ciclicos e de hidroxiacidos ciclicos e seu uso como anticoagulantes
DE60043587D1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
EP1319402A4 (de) IgE-ENTSTEHUNGSHEMMSTOFFE
DK1476470T3 (da) Stivelsesderivater, stivelse-aktivstof-konjugater, fremgangsmåde til fremstilling af disse og anvendelse af disse som lægemidler
BR9814523A (pt) "composição farmacêutica contendo cloridrato de bupropion e um estabilizador de ácido inorgânico"
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
DK1026170T3 (da) Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler
DK0930077T3 (da) Cyclodextrinpræparater indeholdende et avermectin- eller milbemycinderivat
DE60034149D1 (de) Hydrophobe aminosäuren enthaltende trockene zusammensetzung
EP1234875A4 (de) METALLOPROTEASE MIT AGGRECANASE-AKTIVITäT
EP1136080A3 (de) Verwendung von O-Vanillin und O-Vanillin/Trolox Kombinationen
UY27373A1 (es) Formulaciones de interferón beta-humano
FI883643A0 (fi) Cyklopeptider som befraemjar absorption under anvaendning pao slemhinnorna.
HRP20020071B1 (hr) Farmaceutske kompozicije i pripravljanje istih

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1254944

Country of ref document: EP